We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last-reported quarter, Lantheus Holdings’ earnings of 89 cents per share surpassed the Zacks Consensus Estimate by 27.1%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average being 54.6%.
Let’s see how things have shaped up prior to this announcement.
Factors at Play
During the second-quarter 2022 earnings call in August, Lantheus Holdings’ management confirmed that it has been registering a robust uptick in sales of its PYLARIFY, an F 18-labeled PET imaging agent targeting prostate-specific membrane antigen. The favorable adoption of PYLARIFY is expected to have continued in the third quarter on the back of its positive impact of the PSMA-targeted PET imaging on the U.S. prostate cancer community. This is likely to have considerably driven the to-be-reported quarter’s revenues.
During the same call, Lantheus Holdings’ management confirmed that in the European Union, Curium completed its Phase III PYTHON clinical trial for piflufolastat F-18 in May and submitted its marketing authorization application to the European Medicines Agency in June. The company has also worked with Curium to add PYLARIFY to its U.S. ECLIPSE trial. PYLARIFY will be used to determine PSMA avidity as part of patient selection and will now be included in the vast majority of late-stage U.S. trials for the study of PSMA-targeted therapies. These developments buoy our optimism about the stock.
Lantheus Holdings’ ultrasound-enhancing agent, DEFINITY, has been registering strong growth over the past few months, despite headwinds resulting from a decrease in referring physician visits and staffing-related challenges (consistent with the trends noted by other companies in the healthcare sector). Management’s belief that contrast-enhanced echocardiography continues to play an important role in cardiac imaging raises our optimism regarding DEFINITY’s sales in the third quarter.
Over the past few months, Lantheus Holdings has announced positive results from a slew of studies regarding its products. The company is on track to expand its portfolio, evaluate several opportunities to collaborate, and in-license or acquire additional assets. Lantheus Holdings is particularly focused on late-stage diagnostic and therapeutic product opportunities in oncology that complement its existing portfolio. Apart from these, certain early-stage opportunities also align with the strategy that drives its pharma services business. Lantheus Holdings’ recent collaboration agreement with Radiopharm Theranostics is one such example. These raise our optimism about the stock.
The Estimate Picture
For third-quarter 2022, the Zacks Consensus Estimate of $228.5 million for total revenues calls for a surge of 123.9% from the prior-year reported figure.
The consensus estimate for adjusted earnings per share is pegged at 83 cents, indicating a stupendous improvement of 937.5% from the prior-year reported number.
What Our Model Suggests
Our proven model predicts an earnings beat for Lantheus Holdings this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Lantheus Holdings has an Earnings ESP of +3.03%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
National Vision Holdings, Inc. (EYE - Free Report) has an Earnings ESP of +2.56% and a Zacks Rank of 2. EYE has an estimated long-term growth rate of 22.2%.
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has an Earnings ESP of +3.79% and is a Zacks #2 Rank stock. VRTX has an estimated long-term growth rate of 12%.
Vertex Pharmaceuticals’ earnings surpassed estimates in three of the trailing four quarters and missed the same in one, with the average surprise being 3.2%.
GoodRx Holdings, Inc. (GDRX - Free Report) has an Earnings ESP of +21.62% and carries a Zacks Rank of 2 at present. GDRX has an estimated long-term growth rate of 16.4%.
GoodRx’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, with the average surprise being 19.4%.
Image: Bigstock
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
Lantheus Holdings, Inc. (LNTH - Free Report) is scheduled to release third-quarter 2022 results on Nov 3, before the opening bell.
In the last-reported quarter, Lantheus Holdings’ earnings of 89 cents per share surpassed the Zacks Consensus Estimate by 27.1%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average being 54.6%.
Let’s see how things have shaped up prior to this announcement.
Factors at Play
During the second-quarter 2022 earnings call in August, Lantheus Holdings’ management confirmed that it has been registering a robust uptick in sales of its PYLARIFY, an F 18-labeled PET imaging agent targeting prostate-specific membrane antigen. The favorable adoption of PYLARIFY is expected to have continued in the third quarter on the back of its positive impact of the PSMA-targeted PET imaging on the U.S. prostate cancer community. This is likely to have considerably driven the to-be-reported quarter’s revenues.
During the same call, Lantheus Holdings’ management confirmed that in the European Union, Curium completed its Phase III PYTHON clinical trial for piflufolastat F-18 in May and submitted its marketing authorization application to the European Medicines Agency in June. The company has also worked with Curium to add PYLARIFY to its U.S. ECLIPSE trial. PYLARIFY will be used to determine PSMA avidity as part of patient selection and will now be included in the vast majority of late-stage U.S. trials for the study of PSMA-targeted therapies. These developments buoy our optimism about the stock.
Lantheus Holdings, Inc. Price and EPS Surprise
Lantheus Holdings, Inc. price-eps-surprise | Lantheus Holdings, Inc. Quote
Lantheus Holdings’ ultrasound-enhancing agent, DEFINITY, has been registering strong growth over the past few months, despite headwinds resulting from a decrease in referring physician visits and staffing-related challenges (consistent with the trends noted by other companies in the healthcare sector). Management’s belief that contrast-enhanced echocardiography continues to play an important role in cardiac imaging raises our optimism regarding DEFINITY’s sales in the third quarter.
Over the past few months, Lantheus Holdings has announced positive results from a slew of studies regarding its products. The company is on track to expand its portfolio, evaluate several opportunities to collaborate, and in-license or acquire additional assets. Lantheus Holdings is particularly focused on late-stage diagnostic and therapeutic product opportunities in oncology that complement its existing portfolio. Apart from these, certain early-stage opportunities also align with the strategy that drives its pharma services business. Lantheus Holdings’ recent collaboration agreement with Radiopharm Theranostics is one such example. These raise our optimism about the stock.
The Estimate Picture
For third-quarter 2022, the Zacks Consensus Estimate of $228.5 million for total revenues calls for a surge of 123.9% from the prior-year reported figure.
The consensus estimate for adjusted earnings per share is pegged at 83 cents, indicating a stupendous improvement of 937.5% from the prior-year reported number.
What Our Model Suggests
Our proven model predicts an earnings beat for Lantheus Holdings this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Lantheus Holdings has an Earnings ESP of +3.03%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
National Vision Holdings, Inc. (EYE - Free Report) has an Earnings ESP of +2.56% and a Zacks Rank of 2. EYE has an estimated long-term growth rate of 22.2%.
National Vision’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 246.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has an Earnings ESP of +3.79% and is a Zacks #2 Rank stock. VRTX has an estimated long-term growth rate of 12%.
Vertex Pharmaceuticals’ earnings surpassed estimates in three of the trailing four quarters and missed the same in one, with the average surprise being 3.2%.
GoodRx Holdings, Inc. (GDRX - Free Report) has an Earnings ESP of +21.62% and carries a Zacks Rank of 2 at present. GDRX has an estimated long-term growth rate of 16.4%.
GoodRx’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, with the average surprise being 19.4%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.